355 related articles for article (PubMed ID: 30262324)
1. Exploring the surgical landscape of pancreatic neuroendocrine neoplasia in Austria: Results from the ASSO pNEN study group.
Primavesi F; Klieser E; Cardini B; Marsoner K; Fröschl U; Thalhammer S; Fischer I; Hauer A; Urbas R; Kiesslich T; Neureiter D; Zitt M; Klug R; Wundsam H; Sellner F; Karner J; Függer R; Cakar-Beck F; Kornprat P; Öfner D; Stättner S;
Eur J Surg Oncol; 2019 Feb; 45(2):198-206. PubMed ID: 30262324
[TBL] [Abstract][Full Text] [Related]
2. A wait-and-watch approach to small pancreatic neuroendocrine tumors: prognosis and survival.
Massironi S; Rossi RE; Zilli A; Casazza G; Ciafardini C; Conte D
Oncotarget; 2016 Apr; 7(14):18978-83. PubMed ID: 26959887
[TBL] [Abstract][Full Text] [Related]
3. Outcome of surgery for pancreatic neuroendocrine neoplasms.
Fischer L; Bergmann F; Schimmack S; Hinz U; Prieß S; Müller-Stich BP; Werner J; Hackert T; Büchler MW
Br J Surg; 2014 Oct; 101(11):1405-12. PubMed ID: 25132004
[TBL] [Abstract][Full Text] [Related]
4. Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis.
Lindner K; Binte D; Hoeppner J; Wellner UF; Schulte DM; Schmid SM; Luley K; Buchmann I; Tharun L; Keck T; Gebauer J; Kulemann B
Curr Oncol; 2021 Aug; 28(4):3071-3080. PubMed ID: 34436034
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 and presence of liver metastases identify different progression-risk classes in pancreatic neuroendocrine neoplasms (pNEN) undergoing resection.
Milione M; Maisonneuve P; Pellegrinelli A; Spaggiari P; Centonze G; Coppa J; Delconte G; Droz Dit Busset M; Lanhazo O; Pruneri G; Mazzaferro V
Eur J Surg Oncol; 2019 May; 45(5):755-760. PubMed ID: 30366875
[TBL] [Abstract][Full Text] [Related]
6. Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence.
Valente R; Lykoudis P; Tamburrino D; Inama M; Passas I; Toumpanakis C; Luong TV; Davidson B; Imber C; Malagò M; Rahman SH; Shankar A; Sharma D; Caplin M; Fusai G
Eur J Surg Oncol; 2017 Nov; 43(11):2119-2128. PubMed ID: 28821361
[TBL] [Abstract][Full Text] [Related]
7. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
8. Implementation of Current ENETS Guidelines for Surgery of Small (≤2 cm) Pancreatic Neuroendocrine Neoplasms in the German Surgical Community: An Analysis of the Prospective DGAV StuDoQ|Pancreas Registry.
Mintziras I; Keck T; Werner J; Fichtner-Feigl S; Wittel U; Senninger N; Vowinkel T; Köninger J; Anthuber M; Geißler B; Bartsch DK;
World J Surg; 2019 Jan; 43(1):175-182. PubMed ID: 30097704
[TBL] [Abstract][Full Text] [Related]
9. Malignant potential of small pancreatic neuroendocrine neoplasm and its risk factors: A multicenter nationwide study.
Paik WH; Lee HS; Lee KJ; Jang SI; Lee WJ; Hwang JH; Cho CM; Park CH; Han J; Woo SM; Jeong S; Chon HK; Kim TN; Lee JK; Han JH; Yoon JH; Kim YT; Cho JH
Pancreatology; 2021 Jan; 21(1):208-214. PubMed ID: 33281058
[TBL] [Abstract][Full Text] [Related]
10. Can we predict recurrence in WHO G1-G2 pancreatic neuroendocrine neoplasms? Results from a multi-institutional Spanish study.
Ausania F; Senra Del Rio P; Gomez-Bravo MA; Martin-Perez E; Pérez-Daga JA; Dorcaratto D; González-Nicolás T; Sanchez-Cabus S; Tardio-Baiges A
Pancreatology; 2019 Mar; 19(2):367-371. PubMed ID: 30683515
[TBL] [Abstract][Full Text] [Related]
11. Malignant pancreatic neuroendocrine tumour: lymph node ratio and Ki67 are predictors of recurrence after curative resections.
Boninsegna L; Panzuto F; Partelli S; Capelli P; Delle Fave G; Bettini R; Pederzoli P; Scarpa A; Falconi M
Eur J Cancer; 2012 Jul; 48(11):1608-15. PubMed ID: 22129889
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis.
Cloyd JM; Kopecky KE; Norton JA; Kunz PL; Fisher GA; Visser BC; Dua MM; Park WG; Poultsides GA
Surgery; 2016 Sep; 160(3):708-13. PubMed ID: 27216830
[TBL] [Abstract][Full Text] [Related]
13. Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.
Mintziras I; Keck T; Werner J; Fichtner-Feigl S; Wittel U; Senninger N; Vowinkel T; Köninger J; Anthuber M; Geißler B; Bartsch DK;
Surg Today; 2019 Dec; 49(12):1013-1021. PubMed ID: 31240463
[TBL] [Abstract][Full Text] [Related]
14. Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?
Merola E; Rinke A; Partelli S; Gress TM; Andreasi V; Kollár A; Perren A; Christ E; Panzuto F; Pascher A; Jann H; Arsenic R; Cremer B; Kaemmerer D; Kump P; Lipp RW; Agaimy A; Wiedenmann B; Falconi M; Pavel ME
Ann Surg Oncol; 2020 May; 27(5):1348-1355. PubMed ID: 31720931
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
17. The role of lymph node ratio in recurrence after curative surgery for pancreatic endocrine tumours.
Ricci C; Casadei R; Taffurelli G; Buscemi S; D'Ambra M; Monari F; Santini D; Campana D; Tomassetti P; Minni F
Pancreatology; 2013; 13(6):589-93. PubMed ID: 24280574
[TBL] [Abstract][Full Text] [Related]
18. A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.
Sho S; Court CM; Winograd P; Toste PA; Pisegna JR; Lewis M; Donahue TR; Hines OJ; Reber HA; Dawson DW; Tomlinson JS
J Gastrointest Surg; 2019 Jul; 23(7):1392-1400. PubMed ID: 30353489
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors after resection of locally advanced non-functional pancreatic neuroendocrine neoplasm: an analysis from the German Cancer Registry Group of the Society of German Tumor Centers.
Abdalla TSA; Klinkhammer-Schalke M; Zeissig SR; Tol KK; Honselmann KC; Braun R; Bolm L; Lapshyn H; Litkevych S; Zemskov S; Begum N; Kulemann B; Hummel R; Wellner UF; Keck T; Deichmann S
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8535-8543. PubMed ID: 37095413
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery.
Slagter AE; Ryder D; Chakrabarty B; Lamarca A; Hubner RA; Mansoor W; O'Reilly DA; Fulford PE; Klümpen HJ; Valle JW; McNamara MG
Surg Oncol; 2016 Sep; 25(3):223-8. PubMed ID: 27566026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
